US2019010520A1PendingUtilityA1

Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

Assignee: CHARPENTIER EMMANUELLEPriority: May 25, 2012Filed: Sep 19, 2018Published: Jan 10, 2019
Est. expiryMay 25, 2032(~5.8 yrs left)· nominal 20-yr term from priority
H10P 14/6512H10P 14/20A61P 43/00A61P 31/12A61P 31/00A61P 35/00A61P 31/04C12Q 1/686C12N 2310/531A01H 6/4684C12N 2800/80A61K 48/00C12N 15/113C12N 2310/3519C12N 15/907C12N 2310/33C12N 15/63C07K 2319/85C12N 15/90C12N 2310/11C12N 2310/13C12N 15/746A61K 38/465C12N 15/111C12N 9/22C12Y 301/04C12N 15/902C12N 5/10C12N 2310/20C12N 2310/31C12N 15/102A01K 67/027C12N 15/70C12N 2310/14C12N 2310/32C07K 2319/71H10H 20/0137C12N 9/226Y02A50/30
79
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.

Claims

exact text as granted — not AI-modified
1 . A DNA-targeting RNA comprising:
 (i) a first segment comprising a nucleotide sequence that is complementary to a sequence in a target DNA; and   (ii) a second segment that interacts with a site-directed modifying polypeptide.   
     
     
         2 . The DNA-targeting RNA of  claim 1 , wherein the first segment comprises 8 nucleotides that have 100% complementarity to a sequence in the target DNA. 
     
     
         3 . The DNA-targeting RNA of  claim 1 , wherein the second segment comprises a nucleotide sequence with at least 60% identity over a stretch of at least 8 contiguous nucleotides to any one of the nucleotide sequences set forth in SEQ ID NOs:563-682, or a complement thereof. 
     
     
         4 . The DNA-targeting RNA of  claim 1 , wherein the second segment comprises a nucleotide sequence with at least 60% identity over a stretch of at least 8 contiguous nucleotides to any one of the nucleotide sequences set forth in SEQ ID NOs:431-562, or a complement thereof. 
     
     
         5 . The DNA-targeting RNA of  claim 1 , wherein the site-directed modifying polypeptide comprises an amino acid sequence having at least about 75% amino acid sequence identity to amino acids 7-166 or 731-1003 of the Cas9/Csn1 amino acid sequence depicted in  FIG. 3 , or to the corresponding portions in any of the amino acid sequences set forth as SEQ ID NOs:1-256 and 795-1346. 
     
     
         6 . A DNA polynucleotide comprising a nucleotide sequence that encodes the DNA-targeting RNA of  claim 1 . 
     
     
         7 . A recombinant expression vector comprising the DNA polynucleotide of  claim 6 . 
     
     
         8 . The recombinant expression vector of  claim 7 , wherein the nucleotide sequence encoding the DNA-targeting RNA is operably linked to a promoter. 
     
     
         9 . The recombinant expression vector of  claim 8 , wherein the promoter is an inducible promoter. 
     
     
         10 . The recombinant expression vector of  claim 7 , wherein the nucleotide sequence encoding the DNA-targeting RNA of  claim 1  further comprises a multiple cloning site. 
     
     
         11 . An in vitro genetically modified host cell comprising the DNA polynucleotide of  claim 6 . 
     
     
         12 . A recombinant expression vector comprising:
 (i) a nucleotide sequence encoding a DNA-targeting RNA, wherein the DNA-targeting RNA comprises:
 (a) a first segment comprising a nucleotide sequence that is complementary to a sequence in a target DNA; and 
 (b) a second segment that interacts with a site-directed modifying polypeptide; and 
   (ii) a nucleotide sequence encoding the site-directed modifying polypeptide comprising:
 (a) an RNA-binding portion that interacts with the DNA-targeting RNA; and 
 (b) an activity portion that exhibits site-directed enzymatic activity, wherein the site of enzymatic activity is determined by the DNA-targeting RNA. 
   
     
     
         13 . A recombinant expression vector comprising:
 (i) a nucleotide sequence encoding a DNA-targeting RNA, wherein the DNA-targeting RNA comprises:
 (a) a first segment comprising a nucleotide sequence that is complementary to a sequence in a target DNA; and 
 (b) a second segment that interacts with a site-directed modifying polypeptide; and 
   (ii) a nucleotide sequence encoding the site-directed modifying polypeptide, wherein the site-directed modifying polypeptide comprises:
 (a) an RNA-binding portion that interacts with the DNA-targeting RNA; and 
 (b) an activity portion that modulates transcription within the target DNA, wherein the site of modulated transcription within the target DNA is determined by the DNA-targeting RNA. 
   
     
     
         14 .- 155 . (canceled)

Join the waitlist — get patent alerts

Track US2019010520A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.